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Eight manufacturing facilities participating in the National
Institutes of Health–sponsored Clinical Islet Transplanta-
tion (CIT) Consortium jointly developed and implemented
a harmonized process for the manufacture of allogeneic
purified human pancreatic islet (PHPI) product evaluated
in a phase 3 trial in subjects with type 1 diabetes. Manufac-
turing was controlled by a common master production
batch record, standard operating procedures that included
acceptance criteria for deceased donor organ pancreata
and critical raw materials, PHPI product specifications,
certificate of analysis, and test methods. The process was
compliant with Current Good Manufacturing Practices
and Current Good Tissue Practices. This report de-
scribes the manufacturing process for 75 PHPI clinical
1Diabetes Research Institute, Miller School of Medicine, University of Miami,
Miami, FL
2National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD
3Schulze Diabetes Institute and Department of Surgery, University of Minnesota,
Minneapolis, MN
4Department of Surgery, University of California, San Francisco, San Francisco, CA
5Clinical Islet Transplant Program and Faculty of Medicine and Dentistry, University
of Alberta, Edmonton, Alberta, Canada
6Institute for Diabetes, Obesity and Metabolism and Departments of Surgery and
Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
7Division of Transplantation, University of Illinois Hospital and Health Sciences
System, Chicago, IL
8Division of Transplantation, Department of Surgery, Emory Transplant Center,
Emory University, Atlanta, GA
9Clinical Trials Statistical and Data Management Center, University of Iowa, Iowa
City, IA
10National Institute of Diabetes and Digestive and Kidney Diseases, National Insti-
tutes of Health, Bethesda, MD
11Comprehensive Transplant Center, Northwestern University Feinberg School of
Medicine, Chicago, IL
12Division of Transplant Surgery, Massachusetts General Hospital, Harvard Medical
School, Boston, MA
13Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala,
Sweden
14Department of Clinical Immunology, Rudbeck Laboratory, Uppsala University,
Uppsala, Sweden
Corresponding authors: Camillo Ricordi, ricordi@miami.edu, and Julia S. Goldstein,
goldsteinj@niaid.nih.gov.
Received 18 February 2016 and accepted 8 July 2016.
This article contains Supplementary Data online at http://diabetes
.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-0234/-/DC1.
C.R., J.S.G., A.N.B., G.L.S., T.K., C.L., and C.W.C. are the primary authors who
contributed equally to this work.
B.J.H., A.M.P., and A.M.J.S. are the senior authors who contributed equally to
this work.
A.N.B. is currently affiliated with the Islet Cell Laboratory, Cardiovascular
Innovation Institute, Department of Surgery, University of Louisville, Louisville, KY.
D.B.K. is currently affiliated with the University of Wisconsin, Madison, WI.
L.-j.W. is currently affiliated with the Division of Transplantation, University of
Illinois Hospital and Health Sciences System, Chicago, IL.
Additional members of the CIT Consortium are listed in the APPENDIX.
© 2016 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for profit, and the
work is not altered. More information is available at http://www.diabetesjournals
.org/content/license.
See accompanying article, p. 3243.
3418 Diabetes Volume 65, November 2016
IS
L
E
T
S
T
U
D
IE
S
lots and summarizes the results, including lot release.
The results demonstrate the feasibility of implementing
a harmonized process at multiple facilities for the man-
ufacture of a complex cellular product. The quality
systems and regulatory and operational strategies de-
veloped by the CIT Consortium yielded product lots that
met the prespecified characteristics of safety, purity,
potency, and identity and were successfully transplanted
into 48 subjects. No adverse events attributable to the
product and no cases of primary nonfunction were
observed.
Previous clinical trials assessing treatments for unstable
type 1 diabetes have demonstrated restoration of pan-
creatic b-cell function by allogeneic islet transplantation
(1–4). In 2000, the University of Alberta reported that
transplantation of allogeneic purified islet products re-
sulted in sustained C-peptide levels, improved glycemic
control, and prevention of hypoglycemia in seven subjects
with type 1 diabetes (5). The results were later confirmed
by Brennan et al. (6) in a multicenter trial reporting the
12-year follow-up of seven subjects. One subject experi-
enced graft failure 10.9 years post–islet transplantation.
The remaining six continued to have sustained C-peptide
levels and improved glycemic control. No episodes of se-
vere hypoglycemia, opportunistic infections, or lympho-
mas were reported. Although significant progress has
been made since the initial trials, development pathways
for cellular therapy have required convergence toward
regulatory guidelines on clinical trial design. Manufactur-
ing differences at the various processing facilities prevented
comparison of clinical results across centers, making it
difficult to derive overall conclusions and limiting islet
transplantation use in medical practice. Factors affecting
the quality of islet products, including organ donor accep-
tance criteria (7,8), organ recovery techniques, cold ischemia
time (9–11), organ preservation and transport solutions
(12,13), and methods for islet isolation (14), purification,
and culture, have been previously reported (15–17).
Protocol CIT-07 was a prospective, multicenter, single-
arm, pivotal phase 3 trial conducted at eight academic
institutions in North America (Clinical trial reg. no.
NCT00434811, www.clinicaltrials.gov) (18). The trial eval-
uated the safety, tolerability, and efficacy of the purified
human pancreatic islet (PHPI) product in a defined
population of subjects with type 1 diabetes and supported
product licensure in the U.S. The trial was conducted under
a Division of Allergy, Immunology and Transplantation/
National Institute of Allergy and Infectious Diseases
(DAIT/NIAID)–sponsored U.S. Investigational New Drug
application and a Clinical Trial Application in Canada.
Manufacturing information was submitted to a DAIT/
NIAID-sponsored U.S. Drug Master File. A chemistry,
manufacturing, and controls monitoring committee (CMC
MC), with representatives from each manufacturing facility
and DAIT/NIAID, was responsible for the harmonization
of manufacturing processes, including in-process controls,
qualification of manufacturing facilities, definition of product
specifications, and quality oversight.
This article describes the manufacturing process and the
in-process and lot release test results for the 75 clinical lots
transplanted into 48 subjects enrolled in the trial. Each
product was manufactured and transplanted at the same
institution. We report the results of the first successful
standardization of manufacturing processes for the alloge-
neic PHPI product executed at multiple facilities for trans-
plantation to support a pivotal trial. The Clinical Islet
Transplantation (CIT) standard operating procedures
(SOPs) and the master production batch record (MPBR)
developed for product manufacturing are publically available
(19–40). The clinical outcomes are reported elsewhere (18).
RESEARCH DESIGN AND METHODS
Participation in the National Institutes of Health (NIH)-
sponsored CIT Consortium required a demonstrated record
of robust clinical and islet product manufacturing success
(Supplementary Data). The CMC MC developed the com-
mon MPBR (23), product specifications (32), and interim
and final certificates of analysis (COAs) (30,31) and
agreed on the deceased donor organ acceptance criteria
(Table 1). Each manufacturing facility was responsible for
its own quality control, quality assurance, and compliance
with Current Good Manufacturing Practices (cGMP) and
Current Good Tissue Practices. The CMC MC provided
further quality oversight by qualifying the manufactur-
ing facilities for study participation and conducting
batch record reviews. Assays used to determine product
viability (fluorescein diacetate/propidium iodide [FDA/PI])
(33,34,37), identity/quantity (dithizone [DTZ]) (35), and
biological potency (glucose stimulated insulin release
[GSIR] by ELISA) (41) were qualified at each facility be-
fore that facility’s participation in the trial. Manufac-
turers were required to meet the predefined assay
acceptance criteria for accuracy, precision, selectivity,
sensitivity, and reproducibility of each assay. All opera-
tions were conducted using aseptic processing in accredited
cGMP facilities (Supplementary Data).
Pancreas Processing
After arrival of the donor pancreas at the manufacturing
facility, acceptance criteria were verified (Table 1), and a
sample of the preservation solution was taken for sterility
testing. Excess pancreas tissue was removed, and the pan-
creas was weighed (initial weight). The pancreas was then
decontaminated by placing it in Hanks’ balanced salt so-
lution containing 1 g/L cefazolin or 10% povidone iodine
solution.
Perfusion and Distension
The pancreas was divided at the neck to separate the head
from the body and tail. A cannula was placed in the main
pancreatic duct of each section. On the basis of the initial
pancreas weight, the volume of the CIT Enzyme Solution
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(28,29,36) was determined. The pancreas was perfused
with one of three enzyme blend solutions containing a
collagenase and a protease (Table 2). Each enzyme lot
was qualified by three CIT manufacturers by assessing
enzyme activity before its introduction into product
manufacture (23). Each pancreas segment was distended
intraductally by perfusion with cold CIT Enzyme Solution
(28,29,36) either manually or by controlled perfusion
(42–44). Perfusion occurred for 4–10 min at 60–80 mmHg
followed by 4–6 min at 160–180 mmHg at 4–14°C. Final
trimmed pancreas weight was calculated by subtracting
the weight of tissue trimmed during perfusion from the
initial pancreas weight. The perfused pancreas was cut
into 5–15 pieces and placed in a Ricordi digestion cham-
ber (Biorep Technologies, Inc., Miami Lakes, FL).
Digestion Step
Tissue digestion began with recirculation of the Enzyme
Solution (phase 1) to dissociate the pancreas progressively
followed by a dilution phase (phase 2) in which the en-
zymes were neutralized by cooling and dilution with fresh
RPMI medium. For the recirculation phase, the circuit was
primed with CIT Enzyme Solution, and the temperature
was set at 32–38°C. The flow rate was set to 210–250
mL/min until the set temperature was reached and then
reduced to 90–130 mL/min. Freed islets were eluted in
Table 1—Pancreas donor qualifications
Requirement Yes No NA
A qualified donor must have yes responses to all the inclusion criteria (A), and no responses to all the
exclusion criteria (B and C).
Container label must specify human pancreas, and an UNOS or a DDD number must be present.
The organ procurement organization must be identified.
A. Inclusion criteria (The donor or pancreas must meet these criteria.)
1. Pancreas preservation in (i) UW, (ii) PFC/UW, (iii) HTK, or (iv) PFC/HTK solutions
2. Maximum 12-h cold ischemia time
3. Donor age 15–65 years
4. Cause and circumstances of death acceptable to the transplant team
B. Exclusion criteria (Is there evidence of the following conditions?)
1. History or biochemical evidence of type 1 or 2 diabetes (Transplant teams may consider donor
HbA1c .6.1% in the absence of transfusions in the week before death as an indication for exclusion,
with discretion for donors who have received transfusions.)
2. Pancreas from non—heart-beating cardiac death donors
3. Malignancies, other than resected basal squamous cell carcinoma or intracranial tumor as the cause of
death
4. Suspected or confirmed sepsis
5. Evidence of clinical or active viral hepatitis (A, B [HBcAg], C). HBsAb positive is acceptable if there is a
history of vaccination.
6. AIDS
7. HIV seropositivity (HIV-I or HIV-II) or HIV status unknown
8. HTLV-I or HTLV-II (optional)
9. Syphilis (RPR or VDRL positive)
10. Active viral encephalitis or encephalitis of unknown origin
11. TSE or Creutzfeldt-Jakob disease
12. Suspected rabies diagnosis
13. Treated or active tuberculosis
14. Individuals who have received pituitary human growth hormone
15. Any medical condition that, in the opinion of the transplant team, precludes a reasonable possibility of a
favorable outcome of the islet transplant procedure
16. Clinical history and/or laboratory testing suggestive of West Nile virus, vaccinia, or SARS
C. Exclusion criteria—behavioral profiles (Is there evidence of the following conditions?)
17. High-risk sexual behavior within 5 years before time of death: men who have had sex with men,
individuals who have engaged in prostitution, and individuals whose sexual partners have engaged in
high-risk sexual behavior
18. Nonmedical intravenous, intramuscular, or subcutaneous drug use within the past 5 years
19. Persons with hemophilia or related clotting disorders who have received human-derived clotting factor
concentrates
20. Findings on history or physical examination consistent with an increased risk of HIV exposure
21. Current inmates of correctional systems and individuals who have been incarcerated for
.72 consecutive hours during the previous 12 months
DDD, donor-derived disease; HBcAg, hepatitis B core antigen; HBsAb, hepatitis B surface antibody; HTK, histidine-tryptophan-
ketoglutarate; HTLV, human T-cell lymphoma; NA, not applicable; PFC, perfluorocarbon; RPR, rapid plasma reagin; SARS, severe
acute respiratory syndrome; TSE, transmissible spongiform encephalopathy; UNOS, United Network for Organ Sharing; UW, University
of Wisconsin; VDRL, venereal disease research laboratory.
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the diluting buffer and collected. Samples were taken
throughout digestion and assessed by DTZ staining (35)
to determine the time to switch from phase 1 to phase
2 (45). The decision to switch to dilution was based on the
number of islets, percent free islets, and percent frag-
mented islets (23).
During dilution (phase 2), the flow rate was increased
back to 210–250 mL/min, and the temperature was re-
duced to #30°C. If a large number of embedded islets was
observed in samples of the digested product, the temper-
ature was maintained between 30 and 38°C. Dilution was
complete when minimal tissue remained in the chamber
and no islets were observed in the DTZ-stained remaining
tissue. The eluate containing the islets was pooled, centri-
fuged, washed with cold CIT Wash Solution (27), and
resuspended in cold CIT Purification Solution (22).
Purification Step
Twenty-five milliliters or less of digested tissue were
layered over an iodixanol-based continuous density gra-
dient (20), ranging from 1.060 to 1.100 6 0.01 g/mL, and
were centrifuged at 1,800–2,000 rpm in a COBE 2991 cell
processor (Terumo BCT, Lakewood, CO) at 4–8°C. Twelve
25-mL gradient fractions were collected in 250 mL conical
tubes prefilled with 225 mL CMRL 1066, Supplemented,
CIT Modification Solution (Mediatech, Manassas, VA)
(38). Islet purity from each fraction was estimated by DTZ
staining. Purified fractions were classified as high ($70%),
middle (40–69%), and low (30–39%) purity, and those with
the same purity were pooled. If .50,000 islets were present
in fractions with purity ,30%, supplementary purification
was performed using Biocoll (Biochrome AG, Berlin, Germany)
(25), polysucrose discontinuous gradients (Mediatech)
(24), or OptiPrep (Nycomed/Takeda, Osaka, Japan) (26).
Purity of the fractions obtained by supplementary purifi-
cation was assessed by DTZ staining, and each fraction
was combined with fractions of equivalent purity to those
obtained by using the iodixanol-based gradient. From this
point forward, the high-, medium-, and low-purity frac-
tions were processed separately and combined only after
culture and immediately before filling the infusion bags.
Culture Step
Purified islets were cultured for 36–72 h in nontreated
T-175 vented flasks (SARSTEDT AG & Co., Nümbrecht,
Germany) at 10,000–30,000 islet equivalents (IEQ)/30 mL
CIT Culture Media (19). High-purity islet fractions were
cultured at 37°C/5% CO2 for the first 12–24 h and at
22°C/5% CO2 for the remaining time. The middle- and
low-purity fractions were cultured at 22°C/5% CO2 at all
times as previously reported (3,46,47). The media was
removed after the first 24 h and fresh media added.
The cultured islet tissue was collected, washed, pooled,
and resuspended in 50–250 mL CIT Transplant Media
(40) according to islet fraction purity range. The settled
tissue volume was estimated by aspirating each pellet
from the high-, middle-, or low-purity fractions with a
10-mL glass pipette and allowing the aspirate to sedi-
ment by gravity for 5 min. If the combined total settled
tissue volume was #7.5 mL, all purity fractions were
pooled into a single infusion bag. If the total settled
tissue volume was .7.5 and #15 mL, the tissue was
divided into two or three infusion bags, with a maximum
tissue volume of 7.5 mL/bag. The pooled tissue for each
infusion bag was allowed to sediment, washed, and
resuspended in 100 mL CIT Transplant Media (40). The
final product was maintained at room temperature and
transplanted within 6 h of bag fill. Samples for lot release
tests were obtained before filling the infusion bags with
the PHPI final product.
Lot Release
Tests assessed product safety, purity, identity, and po-
tency. Because sterility and biological potency results were
not available at the time of lot release, lots were released
for transplantation by using an interim COA (ICOA)
(Supplementary Data) (31). Safety assessments at the time
of release included microbial contamination by Gram
staining and endotoxin using the limulus amoebocyte lysate
Endosafe-PTS or -KTA2 (Charles River, Charleston, SC). The
final COA (30) was issued when the sterility and postculture
GSIR test results became available (Table 3). The sterility
test was performed compliant with section 610.12 of the
Table 2—Enzyme combinations used in the manufacture of PHPI product
Activity (units) and manufacturer N = 75 Mean (SD) Median Minimum–maximum
Collagenase NB 1 (Wünsch)
46
2,008 (439) 1,829 1,600–3,842
SERVA Electrophoresis, Heidelberg, Germany
Neutral Protease NB (DMC units) 244 (65) 229 200–581
SERVA Electrophoresis
Clzyme (Wünsch)
18
2,472 (542) 2,201 1,620–3,740
VitaCyte, Indianapolis, IN
Neutral Protease NB (DMC units) 199 (45) 183 147–270
SERVA Electrophoresis
Liberase Collagenase I/II MTF (Wünsch)
11
2,678 (302) 2,632 2,426–3,500
Roche Diagnostics, Basel, Switzerland
Liberase Thermolysin (neutral protease units) 99,552 (55,097) 71,577 51,075–187,275
Roche Diagnostics
DMC, dimethylcasein; MTF, mammalian tissue free.
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Code of Federal Regulations Title 21. A preemptive plan
that included the criteria for reporting product contamina-
tion, if a contaminated lot needed to be transplanted for
clinical reasons, was agreed on with the Food and Drug
Administration.
Purity of the PHPI product was defined, not histolog-
ically, but as total IEQ per milliliter of total settled tissue
volume. Viability was assessed by staining with FDA/PI
(Sigma-Aldrich, St. Louis, MO) and expressed as the per-
cent of viable cells (33,34,37) among 50 consecutive islets.
DTZ staining was used for identification of islets, quanti-
fication of IEQ, purity determination, and categorization
by size ranges (35). Biological potency was determined by
the GSIR by ELISA (41), which quantitates the concentra-
tion of insulin secreted in vitro by islets in response to
stimulation with low (2.8 mmol/L) and high (28 mmol/L)
glucose concentrations. The results are expressed as the
stimulation index.
Statistical Methods
Recovery is defined as the quantity of IEQ retrieved
during the manufacturing process and expressed as IEQ
per gram of trimmed pancreas. Process yield refers to the
proportion of IEQ recovered relative to the starting
IEQ. Continuous variables are displayed as number of
observations, mean 6 SD, or median (interquartile range
[IQR]). Categorical variables are displayed as number and
percent. Relationship of donor characteristics to IEQ re-
covery was analyzed by stepwise regression. Comparisons
of variables among enzyme solutions and manufacturing
centers were performed using F tests. Statistical signifi-
cance was defined at P , 0.05. SAS for Windows versions
9.3–9.4 software (SAS Institute, Cary, NC) was used for all
data management and statistical analyses.
RESULTS
A total of 324 pancreata were processed for use in all CIT
clinical protocols. The overall success rate in producing
PHPI lots that met product release criteria was 52.5%
(170 of 324 total CIT lots), which is consistent with
previously reported rates (48–50). Manufacture success
among the centers ranged from 24.5 to 89.5%. The
main factor associated with manufacturing failure was
insufficient number of islets to meet the minimum re-
quired product dose. Subjects in Protocol CIT-07 received
75 of the 170 successfully manufactured PHPI lots, and
the remainder of this report focuses on these 75 lots.
Table 4 shows a side-by-side comparison of the data for
each center and for all centers together and displays the
Table 3—Final COA
Test Method Requirement
Identity
Recipient identity Visual inspection Recipient study ID and recipient medical record number on
this COA and on each infusion bag label identical to that
in the production batch record, section 12.3
Islet identity DTZ stain and microscopic
examination Islets present in each product bag
Volumes in bags
Suspension volume Direct measurement 200 mL per product bag
#600 mL total in three product bags
Settled tissue volume Direct measurement after
5-min settling
#7.5 mL per product bag
#15.0 mL total in three product bags
Potency
GSIR (high-purity islets,
preculture sample) ELISA For information only, report stimulation index
GSIR (high-purity islets,
postculture sample) ELISA Stimulation index .1
Islet quantity DTZ stain and microscopic
examination
First infusion: $5.0 3 103 IEQ/kg recipient BW
(total IEQ/ infusion)
Subsequent infusions: $4.0 3 103 IEQ/kg
recipient BW (total IEQ/infusion)
Viability FDA/PI stain and microscopic
examination $70% in each product bag
Purity
Islet concentration DTZ stain and microscopic
examination $20,000 total IEQ/mL total settled tissue volume
Safety
Appearance Visual inspection Light yellow to amber liquid with visible aggregates
in each product bag
Endotoxins LAL #5.0 EU/kg of recipient BW (total EU/infusion)
Sterility 21 CFR 610.12 No growth in each product bag
CFR, Code of Federal Regulations; EU, endotoxin unit; LAL, limulus amoebocyte lysate.
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rate of successful PHPI preparations. Table 4 also pro-
vides the characteristics of the pancreas donors, interme-
diate and final IEQ recovery, and lot release results. The
intermediate product results included those for the post-
digestion, postpurification, and postculture manufacturing
steps. Values are expressed as median (IQR) as a measure
of variability.
Donor Characteristics
Tables 4 and 5 summarize the pancreas donor physical
characteristics, cause of death, preservation method, and
cold ischemia times. Final recovery of IEQ correlated with
donor sex and BMI (P = 0.0002 and 0.0082, respectively).
No other donor or pancreas characteristics were signifi-
cantly related to IEQ recovery after adjustment for donor
sex and BMI. Differences in donor BMI among centers led
to differences in weight of the trimmed pancreas and
total IEQ recovered per pancreas, but pairwise compari-
sons among centers of IEQ recovery per gram trimmed
pancreas revealed no significant differences after adjust-
ment for multiple comparisons.
Pancreas Perfusion
Lots were manufactured by using a collagenase and a protease
(Table 2). The mean CIT Enzyme Solution volume used dur-
ing perfusion was 403 6 52 mL (range 350–500 mL), and
the mean perfusion time was 11 6 2 min. There was no
significant difference among enzyme blends in the final
recovery of IEQ per gram of trimmed pancreas.
Digestion and Dilution Phases
The mean digestion time (recirculation, phase 1) was 14 6
3 min (range 8–23 min). The decision to switch to dilution
(phase 2) was based on visual examination of 1–2-mL
samples of digested tissue collected from the Ricordi cham-
ber. The following factors were considered: 1) total amount
of digested tissue in the sample, 2) estimated total number
of islets, 3) percent free islets, and 4) percent fragmented
islets. The mean duration of phase 2 was 34 6 9 min
(range 8–57 min). The median (IQR) packed tissue vol-
ume after phase 2 was 44 (16) mL, and contained 708,470
(382,000) IEQ, representing a step recovery of 6,813 (3,672)
IEQ/g trimmed pancreas (Table 4).
Islet Purification
Islet purification was performed by continuous density
gradient centrifugation with a COBE 2991 cell processor.
The maximum tissue volume purified in each COBE run
was 25 mL. All COBE operations were performed at
2–8°C. Of the 75 lots manufactured and transplanted,
52 (69.3%), 10 (13.3%), 9 (12%), and 4 (5.3%) required
two, three, one, and four COBE runs, respectively, for islet
purification from the digested tissue. Postpurification is-
let recovery (total IEQ) was 582,370 (267,931) IEQ,
representing 5,471 (2,709) IEQ/g trimmed pancreas. Be-
fore culture, fractions were combined based on relative
purity (high $70%, medium 40–69%, low #40%) as de-
termined by DTZ staining (35). The purification step me-
dian yield was 82% (22%) of the islets present in the
postdigestion intermediate product (Table 4).
Islet Culture
Purified islets were cultured for 36–72 h before transplan-
tation. For the first 12–24 h, high-purity islet fractions
were incubated at 37°C/5% CO2, and middle- and low-
purity islet fractions were incubated at 22°C/5% CO2 as
previously described (3,46,47). All fractions were cultured
at 22°C/5% CO2 for the remainder of the culture period.
Median total islet count postculture was 490,174 (226,835)
IEQ, representing a total islet recovery of 4,730 (2,156)
IEQ/g trimmed pancreas. Median islet yield for the culture
step was 86% (17%). Median total process yield, calcu-
lated from postdigestion to postculture, was 71% (22%)
(Table 4).
PHPI Product Characteristics and Lot Release
PHPI final product was released on the basis of the results
reported on the ICOA (Supplementary Data) (31). Each
PHPI product lot was defined as the purified pancreatic
islets isolated during a single purification run from a sin-
gle deceased donor pancreas and administered to a single
recipient. Twenty-two subjects received one dose of PHPI
by intraportal infusion, and 25 and 1 received two and
three doses, respectively. Additional details of doses for
first, second, and third infusions are included in the Sup-
plementary Data. The initial transplant required a dose
of $5,000 IEQ/kg recipient body weight (BW), and the
second and third required a dose of $4,000 IEQ/kg re-
cipient BW (Table 6). The median total PHPI dose per
subject was 11,972 IEQ/kg (range 5,227–25,553 IEQ/kg),
with 42 of 48 subjects achieving clinical success (18).
Table 5—Additional donor and pancreas characteristics
Category n (%)
Sex
Male 53 (70.7)
Female 22 (29.3)
Cause of death
Anoxia 4 (5.3)
Cerebrovascular accident 33 (44)
Head trauma 34 (45.3)
Other 4 (5.3)
Cardiac arrest
No 59 (78.7)
Yes 7 (9.3)
Unknown 9 (12)
Preservation method
UW 47 (62.7)
PFC/UW 8 (10.7)
HTK 14 (18.7)
PFC/HTK 3 (4)
Not specified 3 (4)
HTK, histidine-tryptophan-ketoglutarate; PFC, perfluorocarbon;
UW, University of Wisconsin.
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Each of the 75 PHPI lots was released for trans-
plantation in 1 (n = 54), 2 (n = 20), or 3 (n = 1) infusion
bags. The median settled tissue volume was 4.0 (3.8)
mL and contained 6,694 (2,800) IEQ/kg recipient BW at
a concentration of 134,813 (131,407) IEQ/mL settled
tissue. Median viability was 94% (6%) in the high-purity
sample, and the median GSIR stimulation index was 2.3
(1.6) (Table 4). For all 75 PHPI lots, Gram stain was
negative, and the endotoxin concentration was #5.0 en-
dotoxin units/kg recipient BW.
Sterility tests were performed in samples of the pres-
ervation solution and the final product (Supplementary
Data); 22 of 75 preservation solution samples were con-
taminated with skin saprophytes and 1 of 75 contained
Candida albicans. For the final product, the sterility tests
of 5 of 75 lots showed skin saprophytes, and 1 lot
contained C. albicans (for the same lot that reported the
presence of C. albicans in the preservation solution). Per
CIT Consortium and site-specific procedures, in all cases,
the site investigators were immediately notified. The sub-
ject who received the lot contaminated with C. albicans
received fluconazole prophylactically. None of the recipi-
ents of these six lots exhibited signs or symptoms of in-
fection posttransplantation. No adverse effects attributable
to the investigational product were reported for any recip-
ient. All lots met the interim lot release criteria. After
transplantation, positive sterility test results were reported
for six product lots, and two lots failed the GSIR specifica-
tion. All other lots met the final release criteria.
DISCUSSION
The methods for large-scale isolation and purification of
adult human pancreatic islets have substantially improved
over the past three decades as a result of major collab-
orative efforts among several centers in North America
and Europe (1,51–53). Advancements in islet processing
technology, immunosuppression, immunomodulation, and
peritransplant anti-inflammatory strategies have contributed
to progressive improvement of clinical results. However, the
lack of standardization of islet processing methods may
have contributed to the variability of outcomes across
centers and reduced the ability to compare results, even
when the same clinical protocol and immunosuppressive
regimen were used.
Previously reported differences in outcome among
centers highlighted the challenges of the manufacturing
process for pancreatic islets in addition to those related to
immunosuppression management in islet allotransplanta-
tion (4,16). The Edmonton trial conducted at nine centers
resulted in a variable success rate (0–100%) for the pri-
mary end point, with all cases of primary nonfunction
occurring at two of the three centers at which no subject
achieved the primary end point (4). Islet products were
transplanted immediately after processing, which may not
have allowed time to evaluate the quality of the product.
Given previous experience, to minimize the risk of pri-
mary nonfunction, purified islets were cultured to permit
quality control before product release for transplantation
(45,46).
Quality of the islet products was affected by donor
characteristics, organ recovery and preservation, islet iso-
lation, purification, and culture methods (7,10,14–17). The
CIT investigators recognized the need for a major effort in
standardization of the PHPI manufacturing process to allow
for meaningful comparison of clinical trial outcomes across
sites. The investigators also recognized the need to define
stringent donor selection criteria and to define and de-
velop process improvements based on acquired experi-
ence that would consistently yield a high-quality islet
product (53).
We report the methods and results of a common man-
ufacturing protocol, representing the convergence of
several years of teamwork by eight academic institutions
to optimize and standardize processes, criteria, and test
methods across islet transplantation centers. A major
standardization effort was undertaken to ensure product
and process consistency and to test method reproducibil-
ity across participating manufacturers. The CIT collabo-
rative effort resulted in the implementation of a defined
set of critical process parameters and in-process controls
for PHPI production reflected in the common MPBR and
SOPs executed at the eight CIT processing facilities.
Among the key raw materials, we identified the donor
pancreas and the enzyme blends as critical components
of the PHPI manufacturing process. In 2007, the most
widely used enzyme for manufacture of islet products
became unavailable. This unforeseen limitation forced
our group to reevaluate, test, and qualify additional
proteolytic replacement enzymes. The CIT efforts re-
sulted in the successful identification and testing of
new enzyme blends by the manufacturing centers. The
results presented here show that the enzymes used in
digestion yielded lots that met the product specifica-
tion and, therefore, could be used in manufacturing the
PHPI product.
Table 6—Final product formulation for PHPIs
Ingredient Quantity
Active ingredient
Human pancreatic islets First infusion: $5.0 3 103
IEQ /kg recipient BW
(total IEQ/infusion)
Subsequent infusion:
$4.0 3 103 IEQ /kg
recipient BW (total IEQ/
infusion)
Inactive ingredients
CMRL 1066 transplant
media (n = 12) containing
HEPES without sodium
bicarbonate q.s. to 200 mL per bag
Albumin human, USP 2.5%
q.s., sufficient quantity; USP, U.S. Pharmacopeia.
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During the trial, potency was assessed by viability and
identity of islets as determined by FDA/PI (33,34,37) and
DTZ stain (35), respectively. The CMC MC developed
and standardized a GSIR by ELISA (41) for quality control
and as an in vitro assay for potency assessment of PHPI
products. The GSIR assay provided a quantitative measure
of the biological activity by determining the amount of in-
sulin released in response to glucose stimulation (Table 4).
During the conduct of Protocol CIT-07, all lots were
released on the basis of an ICOA and met lot release
specifications (Supplementary Data). As previously stated,
the GSIR results of the final product were not available
before transplantation. Additional studies may determine
whether the GSIR should become a component of the
matrix of functional assays for lot release.
The clinical trial results show that the PHPI product
was well-tolerated, safe, and effective in the specific type 1
diabetes population (18). These results were obtained de-
spite a range of donor characteristics (BMI 33.4 [8.2]
kg/m2, donor ages 42 [19] years, cold ischemia times 7.7
[3.4] h) and median PHPI dose (11,972 [range 5,227–
25,553] IEQ/kg).
This report is the first of the successful standardiza-
tion of the manufacture of a defined complex biological
cellular product for the treatment of type 1 diabetes with
hypoglycemia across multiple manufacturing facilities for
a license-enabling trial. The cGMP manufacturing process
defined in the common CIT documents yielded product
lots that met the prespecified criteria for safety, purity,
potency, and identity. These results show that the CIT
manufacturers achieved consistent and reproducible re-
sults across participating centers. No case of primary
nonfunction was observed after transplantation of PHPI
lots (18). The manufacturing and clinical data generated
in this study will be available to CIT and non-CIT sites to
facilitate licensure by the Food and Drug Administration.
Product licensure will be important to improve patient
access (with third-party coverage) to PHPI transplantation
and to facilitate the development of second-generation islet
products (e.g., stem cells, xenogeneic, encapsulated).
Acknowledgments. The authors thank the collaborators in the CIT
Consortium, particularly those involved with the manufacture of PHPI. Facilities
that manufactured the PHPI product transplanted to Protocol CIT-07 subjects were
the Diabetes Research Institute, Miller School of Medicine, University of Miami,
Miami, FL; Schulze Diabetes Institute and Department of Surgery, University of
Minnesota, Minneapolis, MN; Department of Surgery, University of California, San
Francisco, San Francisco, CA; Clinical Islet Transplant Program and Faculty of
Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Institute
for Diabetes, Obesity and Metabolism and Departments of Surgery and Medicine,
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Division
of Transplantation, University of Illinois Hospital and Health Sciences System,
Chicago, IL; Division of Transplantation, Department of Surgery, Emory Transplant
Center, Emory University, Atlanta, GA; and Comprehensive Transplant Center,
Northwestern University Feinberg School of Medicine, Chicago, IL. The authors
acknowledge Nordmark Arzneimittel GmbH & Co. KG/SERVA Electrophoresis GmbH
and Biorep Technologies, Inc., for generously supplying products.
Funding. This research was supported by grants from the National Institute of
Allergy and Infectious Diseases and the National Institute for Diabetes and
Digestive and Kidney Diseases to the following institutions: Emory University
(Atlanta, GA), U01-AI-089317; Northwestern University (Evanston, IL), U01-AI-
089316; University of Alberta (Edmonton, Alberta, Canada), U01-AI-065191;
University of California, San Francisco (San Francisco, CA), U01-DK-085531;
University of Illinois at Chicago (Chicago, IL), 5U01-DK-070431-10; University
of Iowa (Iowa City, IA), U01-DK-070431; University of Miami (Miami, FL), U01-
DK-070460; University of Minnesota (Minneapolis, MN), U01-AI-065193; Univer-
sity of Pennsylvania (Philadelphia, PA), U01-DK-070430; and Uppsala University
(Uppsala, Sweden), U01-AI- 065192. In addition, the study was supported by the
following General Clinical Research Center Awards and Clinical and Translational
Science Awards: Emory University, UL1-TR-000454; Northwestern University,
5UL1-RR-025741 and 8UL1-TR-000150; University of California, San Francisco,
UL1-TR-000004; University of Illinois at Chicago, UL1-TR-000050; University
of Miami, 1UL1-TR-000460; University of Minnesota, 5M01-RR-000400
and UL1-TR-000114; and University of Pennsylvania, M01-RR-00040 and UL1-
TR-000003.
Duality of Interest. The following authors reported potential conflicts of
interest: C.R. is the coinventor on patents related to islet isolation processing
aspects that are in part used for current islet cell product manufacturing (does
not receive any royalty or financial benefit from these patents or from islet cell
processing activities); J.F.M., ViCapsys (consultant); J.O., Novartis (speaker,
grant), Pfizer (grant), Novo Nordisk (grant), and Semma Therapeutics (consultant);
B.J.H., Sanofi (consultant), Novartis (consultant), and Dompé (consultant); and
P.G.S., Genzyme (personal fees), Sanofi (personal fees), Eli Lilly (personal fees),
Novo Nordisk (grant, personal fees), and Conatus (nonfinancial support). No other
potential conflicts of interest relevant to this article were reported.
Author Contributions. C.R., A.N.B., B.B., J.C., A.K., E.L., D.B., X.C.,
A.S.F., J.L., L.-j.W., J.J.W., J.W., and X.Z. contributed to the study concept and
design; concept and development of the MPBRs, process SOPs, product
specifications, and COA; study conduct; data acquisition, analysis, and
interpretation; and writing, review, and final approval of the manuscript. J.S.G.
led the CMC MC and contributed to the study concept and design; concept and
development of the MPBRs, process SOPs, product specifications, and COA;
oversight for the PHPI manufacturing and qualification of sites for participation in
the protocol; development of the regulatory strategy and the PHPI manufacturing
process; study conduct; data acquisition, analysis, and interpretation; and
writing, review, and final approval of the manuscript. G.L.S., T.K., and C.L.
contributed to the study concept and design; concept and development of the
MPBRs, process SOPs, product specifications, and COA; design, analysis, and
interpretation of PHPI manufacturing results; study conduct; data acquisition,
analysis, and interpretation; and writing, review, and final preparation and
approval of the manuscript. C.W.C. contributed to the study concept and design;
concept and development of the MPBRs, process SOPs, product specifications,
and COA; development of the regulatory strategy and the PHPI manufacturing
process; design, analysis, and interpretation of PHPI manufacturing results; study
conduct; data acquisition, analysis, and interpretation; and writing, review, and
final preparation and approval of the manuscript. N.D.B., T.L.E., and L.G.H.
contributed to the study concept and design, data analysis, and writing, review,
and final editing and approval of the manuscript. W.R.C., D.B.K., D.-E.L., X.L.,
J.F.M., A.N., O.K., J.O., N.A.T., B.J.H., A.M.P., P.G.S., and A.M.J.S. contributed to
the study concept and design, data analysis, and writing, review, and final approval
of the manuscript. C.R., J.S.G., and A.N.B. are the guarantors of this work and, as
such, had full access to all the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
Appendix
Consortium Members
The National Institutes of Health CIT CMC MC. J. Ansite, A.N. Balamurugan,
B. Barbaro, J. Battle, D. Brandhorst, J. Cano, X. Chen, S. Deng, D. Feddersen,
A. Friberg, T. Gilmore, J.S. Goldstein, T. Granderson, E. Holbrook, A. Khan, T. Kin,
3426 NIH-CIT Phase 3 Trial—Islet Manufacturing Diabetes Volume 65, November 2016
J. Lei, E. Linetsky, C. Liu, K. McElvany, Z. Min, J. Moreno, D. O’Gorman, K.K.
Papas, G. Putz, C. Ricordi, G.L. Szot, L. Wang, J.J. Wilhelm, J. Willits, and
X. Zhang
NIH-CIT Consortium
Emory University. J. Avila, B. Begley, J. Cano, S. Carpentier, E. Holbrook,
J. Hutchinson, C.P. Larsen, J. Moreno, M. Sears, N.A. Turgeon, and D. Webster
Massachusetts General Hospital. S. Deng, J. Lei, and J.F. Markmann
National Institute of Allergy and Infectious Diseases. N.D. Bridges, C.W.
Czarniecki, J.S. Goldstein, T. Granderson, and G. Putz
National Institute of Diabetes and Digestive and Kidney Diseases. T.L.
Eggerman
Northwestern University. P. Al-saden, J. Battle, X. Chen, A. Hecyk, H. Kissler,
X. Luo, M. Molitch, N. Monson, E. Stuart, A. Wallia, S. Wang, and X. Zhang
University of Alberta. D. Bigam, P. Campbell, P. Dinyari, T. Kin, N. Kneteman,
J. Lyon, A. Malcolm, D. O’Gorman, C. Onderka, R. Owen, R. Pawlick, B. Richer,
S. Rosichuk, D. Sarman, A. Schroeder, P.A. Senior, A.M.J. Shapiro, L. Toth,
V. Toth, and W. Zhai
University of California, San Francisco. K. Johnson, J. McElroy, A.M. Posselt,
M. Ramos, T. Rojas, P.G. Stock, and G.L. Szot
University of Illinois at Chicago. B. Barbaro, J. Martellotto, J. Oberholzer, M. Qi,
L. Wang, and Y. Wang
University of Iowa (Data Coordinating Center). L. Bayman, K. Chaloner,
W. Clarke, J.S. Dillon, C. Diltz, G.C. Doelle, D. Ecklund, D. Feddersen, E. Foster,
L.G. Hunsicker, C. Jasperson, D.-E Lafontant, K. McElvany, T. Neill-Hudson,
D. Nollen, J. Qidwai, H. Riss, T. Schwieger, B. Shields, J. Willits, and J. Yankey
University of Miami. R. Alejandro, A. Alvarez, A.C. Corrales, R. Faradji, T. Froud,
A.A. Garcia, E. Herrada, H. Ichii, L. Inverardi, N. Kenyon, A. Khan, E. Linetsky,
J. Montelongo, E. Peixoto, K. Peterson, C. Ricordi, J. Szust, and X. Wang
University of Minnesota. M.H. Abdulla, J. Ansite, A.N. Balamurugan, M.D.
Bellin, M. Brandenburg, T. Gilmore, J.V. Harmon, B.J. Hering, R. Kandaswamy,
G. Loganathan, K. Mueller, K.K. Papas, J. Pedersen, J.J. Wilhelm, and J. Witson
University of Pennsylvania. C. Dalton-Bakes, M. Kamoun, J. Kearns, Y. Li, C.
Liu, E. Luning-Prak, Y. Luo, E. Markmann, Z. Min, A. Naji, M. Palanjian,
M. Rickels, R. Shlansky-Goldberg, K. Vivek, and A.S. Ziaie
University of Wisconsin. L. Fernandez, D.B. Kaufman, and L. Zitur
Uppsala University. D. Brandhorst, A. Friberg, and O. Korsgren
References
1. Ricordi C, Strom TB. Clinical islet transplantation: advances and immuno-
logical challenges. Nat Rev Immunol 2004;4:259–268
2. Markmann JF, Deng S, Huang X, et al. Insulin independence following
isolated islet transplantation and single islet infusions. Ann Surg 2003;237:741–
749
3. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose
islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830–835
4. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton
protocol for islet transplantation. N Engl J Med 2006;355:1318–1330
5. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients
with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive
regimen. N Engl J Med 2000;343:230–238
6. Brennan DC, Kopetskie HA, Sayre PH, et al. Long-term follow-up of the
Edmonton protocol of islet transplantation in the United States. Am J Transplant
2016;16:509–517
7. Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that
affect the recovery of human islets of Langerhans. Transplantation 1996;61:
1047–1053
8. Kin T. Islet isolation for clinical transplantation. Adv Exp Med Biol 2010;654:
683–710
9. Brandhorst H, Hering BJ, Brandhorst D, Federlin K, Bretzel RG. Impact of
cold ischemia and timing of intraductal collagenase distension on human islet
yield, purity, viability, and survival in low temperature culture. Transplant Proc
1994;26:590–591
10. Kin T, Mirbolooki M, Salehi P, et al. Islet isolation and transplantation
outcomes of pancreas preserved with University of Wisconsin solution versus
two-layer method using preoxygenated perfluorocarbon. Transplantation 2006;
82:1286–1290
11. Yamamoto T, Horiguchi A, Ito M, et al. Quality control for clinical islet
transplantation: organ procurement and preservation, the islet processing facility,
isolation, and potency tests. J Hepatobiliary Pancreat Surg 2009;16:131–136
12. Brandhorst H, Hering BJ, Brandhorst D, et al. Comparison of histidine-
tryptophane-ketoglutarate (HTK) and University of Wisconsin (UW) solution for
pancreas perfusion prior to islet isolation, culture and transplantation. Transplant
Proc 1995;27:3175–3176
13. Iwanaga Y, Sutherland DE, Harmon JV, Papas KK. Pancreas preservation for
pancreas and islet transplantation. Curr Opin Organ Transplant 2008;13:135–141
14. Lakey JR, Burridge PW, Shapiro AM. Technical aspects of islet preparation
and transplantation. Transpl Int 2003;16:613–632
15. Noguchi H, Miyagi-Shiohira C, Kurima K, et al. Islet culture/preservation
before islet transplantation. Cell Med 2015;8:25–29
16. Balamurugan AN, Bottino R, Giannoukakis N, Smetanka C. Prospective and
challenges of islet transplantation for the therapy of autoimmune diabetes.
Pancreas 2006;32:231–243
17. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in
islet transplantation. Am J Transplant 2004;4:295–298
18. Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 trial of transplantation of
human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes
Care 2016;39:1230–1240
19. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets (PHPI), CIT culture media—a standard operating procedure of the NIH
Clinical Islet Transplantation Consortium. CellR4 2014;2:e981
20. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT purification density gradient—standard operating procedure of the NIH
Clinical Islet Transplantation Consortium. CellR4 2014;2:e991
21. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT digestion solution—a standard operating procedure of the NIH Clinical
Islet Transplantation Consortium. CellR4 2014;2:e985
22. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT purification solution—a standard operating procedure of the NIH
Clinical Islet Transplantation Consortium. CellR4 2014;2:e993
23. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets (PHPI) master production batch record—a standard operating procedure of
the NIH Clinical Islet Transplantation Consortium. CellR4 2014;2:e891
24. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, supplementary purification, discontinuous polysucrose procedure &
record—a standard operating procedure of the NIH Clinical Islet Trans-
plantation Consortium. CellR4 2014;2:e997
25. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, supplementary purification, Biocoll procedure & record—a standard op-
erating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4
2014;2:e995
26. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, supplementary purification, OptiPrep procedure and record—a standard
operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4
2014;2:e999
27. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT wash solution—a standard operating procedure of the NIH Clinical Islet
Transplantation Consortium. CellR4 2014;2:e989
28. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT enzyme solution Roche enzymes—standard operating procedure of the
NIH Clinical Islet Transplantation Consortium. CellR4 2015;3:e1360
29. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT enzyme solution—VitaCyte Enzymes and VitaCyte/SERVA Enzymes
Combination—standard operating procedure of the NIH Clinical Islet Trans-
plantation Consortium. CellR4 2015;3:e1350
diabetes.diabetesjournals.org Ricordi and Associates 3427
30. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, certificate of analysis (product code PHPI-A-01)—standard operating
procedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2015;3:
e1448
31. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic islets,
interim certificate of analysis (product code PHPI-A-01)—standard operating pro-
cedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2015;3:e1446
32. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, specification (product codes PHPI-A-01, PHPI-L-01, PHPI-E-01)—standard
operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4
2015;3:e1437
33. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islet—viability estimation of islet using fluorescent dyes (FDA/PI)—standard
operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4
2015;3:e1378
34. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic islet,
viability estimation of islet using fluorescent dyes, attachment II, islet viability
worksheet—standard operating procedure of the NIH Clinical Islet Trans-
plantation Consortium. CellR4 2015;3:e1376
35. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic islet:
qualitative and quantitative assessment of islets using dithizone (DTZ)—standard
operating procedure of the NIH Clinical Islet Transplantation Consortium. CellR4
2015;3:e1369
36. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets CIT Enzyme Solution: SERVA enzymes proportional units collagenase &
neutral protease—standard operating procedure of the NIH Clinical Islet Trans-
plantation Consortium. CellR4 2015;3:e1342
37. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic islet,
viability estimation of islet using fluorescent dyes, attachment I, preparation of
fluorescein diacetate and propidium iodine solutions—standard operating pro-
cedure of the NIH Clinical Islet Transplantation Consortium. CellR4 2015;3:e1374
38. Ansite J, Balamurugan AN, Barbaro B, et al. Raw material specification,
CMRL 1066, supplemented, CIT modifications—standard operating procedure of
the NIH Clinical Islet Transplantation Consortium. CellR4 2016;4:e1895
39. Ansite J, Balamurugan AN, Barbaro B, et al. Raw material specification,
human pancreas, deceased donor—standard operating procedure of the NIH
Clinical Islet Transplantation Consortium. CellR4 2016;4:e1932
40. Ansite J, Balamurugan AN, Barbaro B, et al. Purified human pancreatic
islets, CIT transplant media—standard operating procedure of the NIH Clinical
Islet Transplantation Consortium. CellR4 2015;3:e1523
41. Ansite J, Balamurugan AN, Barbaro B, et al. Functional assessment of
purified human pancreatic islets: glucose stimulated insulin release by ELISA—a
standard operating procedure of the NIH Clinical Islet Transplantation Consortium.
CellR4 2014;2:e900
42. Lakey JR, Warnock GL, Shapiro AM, et al. Intraductal collagenase delivery
into the human pancreas using syringe loading or controlled perfusion. Cell
Transplant 1999;8:285–292
43. Warnock GL, Lakey JR, Ao Z, Rajotte RV. Tissue banking of cryopreserved
islets for clinical islet transplantation. Transplant Proc 1994;26:3438
44. Papas KK, Suszynski TM, Colton CK. Islet assessment for transplantation.
Curr Opin Organ Transplant 2009;14:674–682
45. Kissler HJ, Niland JC, Olack B, et al. Validation of methodologies for
quantifying isolated human islets: an Islet Cell Resources study. Clin Transplant
2010;24:236–242
46. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured
islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3
antibody. Am J Transplant 2004;4:390–401
47. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes
mellitus using cultured islets and steroid-free immunosuppression: Miami ex-
perience. Am J Transplant 2005;5:2037–2046
48. Cross SE, Hughes SJ, Partridge CJ, Clark A, Gray DW, Johnson PR.
Collagenase penetrates human pancreatic islets following standard intraductal
administration. Transplantation 2008;86:907–911
49. Shapiro AM. Strategies toward single-donor islets of Langerhans trans-
plantation. Curr Opin Organ Transplant 2011;16:627–631
50. Balamurugan AN, Loganathan G, Bellin MD, et al. A new enzyme mixture to
increase the yield and transplant rate of autologous and allogeneic human islet
products. Transplantation 2012;93:693–702
51. Piemonti L, Pileggi A. 25 years of the Ricordi automated method for islet
isolation. CellR4 2013;1:e128
52. Ricordi C. Islet transplantation: a brave new world. Diabetes 2003;52:1595–
1603
53. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of
clinical islet transplantation: 1999-2010. Diabetes Care 2012;35:1436–1445
3428 NIH-CIT Phase 3 Trial—Islet Manufacturing Diabetes Volume 65, November 2016
